Covaxin

An ICMR study has indicated that a booster dose of Covaxin is safe and necessary to ensure persistent immunity to minimise breakthrough infections of COVID-19, Minister of State for Health Bharati Pravin Pawar informed Parliament on Friday.

Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.

The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.

Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16

The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.

The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada

CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world health body's emergency use approval for the jab.

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.

An ICMR study has indicated that a booster dose of Covaxin is safe and necessary to ensure persistent immunity to minimise breakthrough infections of COVID-19, Minister of State for Health Bharati Pravin Pawar informed Parliament on Friday.

Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.

The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.

Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.

Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16

The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.

The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada

CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Centre said that reports apparently quoting a communication from the MEA asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval nod for its COVID jab, "potrayed an incorrect picture."

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world health body's emergency use approval for the jab.

Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.

The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.